Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,21%
1 091,51
-2,30
-0,21%
—1 093,811 096,521 100,221 091,51——
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
—608,77608,77612,97608,77——
SIXE
Energy
SIXE
Energy
SIXE
-1,34%
1 237,98
-16,83
-1,34%
—1 254,811 253,011 253,871 226,33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,93%
1 744,71
-16,40
-0,93%
—1 761,111 764,271 766,881 744,71——
SIXM
Financials
SIXM
Financials
SIXM
-0,37%
640,18
-2,40
-0,37%
—642,58644,87648,48640,18——
SIXR
Staples
SIXR
Staples
SIXR
-0,18%
849,58
-1,55
-0,18%
—851,13855,66858,75845,56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,23%
217,48
-0,50
-0,23%
—217,98217,98218,65216,88——
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3 260,69
+48,86
+1,52%
—3 211,833 227,213 268,383 226,55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,69%
942,45
-6,53
-0,69%
—948,98948,58957,83941,97——
SIXV
Health care
SIXV
Health care
SIXV
-0,52%
1 466,80
-7,72
-0,52%
—1 474,521 479,031 481,041 466,80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2 397,50
+5,38
+0,22%
—2 392,122 396,952 421,222 382,32——
Q1 2026 earnings • in 3 days
See details
BMRN:NASDAQ
Biomarin Pharmaceutical Inc
54,06 USD
+0,28%
(+0,15) 1D
54,06 USD
-0,00% (-0,00010)
After hours
Closed: 1-май, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BMRN...
Open
53,91 USD
High
54,29 USD
Low
53,56 USD
Mkt. cap
10,45 млд
Avg. vol.
1,83 млн
Volume
1,34 млн
P/E ratio
29,96
52-wk high
66,28 USD
52-wk low
50,76 USD
EPS
1,80 USD
Beta
0,29
Shares outstanding
192,32 млн
No. of employees
3 миң
News stories
From sources across the web
Profile
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria. Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
About Biomarin Pharmaceutical Inc
CEOAlexander Hardy
Employees3,22 миң
Foundedмар. 1997
HeadquartersСан Рафаел, Калифорния, Америка Кошмо Штаттары
Sector-
Websitebiomarin.com
Next call 3 күндөн кийин
4-май, дүй., 16:30
Fiscal Period
Q1 2026
Normalized EPS / Estimate
-/ (0,91 est.)USD
Revenue / Estimate
-/ (751,68 млн est.)USD
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earningsInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025-ж. мар.
2025-ж. июн.
2025-ж. сен.
2025-ж. дек.
Revenue
745,14 млн
825,41 млн
776,13 млн
874,56 млн
Cost of goods sold
310,29 млн
311,40 млн
549,56 млн
348,91 млн
Cost of revenue
310,29 млн
311,40 млн
549,56 млн
348,91 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
206,12 млн
232,28 млн
268,42 млн
324,16 млн
Operating expense
210,96 млн
237,12 млн
273,26 млн
329,01 млн
Total operating expenses
521,25 млн
548,52 млн
822,82 млн
677,92 млн
Operating income
223,89 млн
276,89 млн
-46,69 млн
196,64 млн
Other non operating income
-1,95 млн
4,83 млн
5,09 млн
1,02 млн
EBT including unusual items
238,09 млн
297,87 млн
-26,32 млн
-27,15 млн
EBT excluding unusual items
238,09 млн
297,87 млн
-26,32 млн
214,10 млн
Income tax expense
52,40 млн
57,34 млн
4,42 млн
19,42 млн
Effective tax rate
22,01%
19,25%
-16,79%
-71,52%
Other operating expenses
-
-
-
-
Net income
185,69 млн
240,53 млн
-30,74 млн
-46,57 млн
Net profit margin
24,92%
29,14%
-3,96%
-5,33%
Earnings per share
1,13
1,44
0,12
0,46
Interest and investment income
19,01 млн
18,83 млн
17,85 млн
19,21 млн
Interest expense
-2,86 млн
-2,68 млн
-2,58 млн
-2,78 млн
Net interest expenses
16,15 млн
16,15 млн
15,28 млн
16,43 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
245,96 млн
295,45 млн
-28,20 млн
209,68 млн
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer